Navigation Links
For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
Date:4/30/2013

BURLINGTON, Mass., April 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European infectious disease specialists agree that effect on recurrence rate is one of the drug attributes that most influences their prescribing decisions when treating Clostridium difficile infections (CDIs). Similarly, surveyed hospital pharmacy directors indicate a high willingness to grant favorable formulary status to therapies that can demonstrate a decrease in recurrence rates of CDIs. However, even though clinical data and interviewed key opinion leaders indicate that emerging therapies provide a significant advantage over current standard-of-care therapies, marketers will need to be cognizant of price in a CDI market dominated by inexpensive and efficacious alternatives.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled Market Opportunity Awaits Therapies That Provide Low Rates of CDI Recurrences finds that surveyed U.S. infectious disease specialists would prescribe Cubist's surotomycin to 15 percent of their CDI patients, driven mostly by surotomycin's lower rate of CDI recurrence relative to oral vancomycin (ViroPharma's Vancocin; generics). However, Decision Resources forecasts that surotomycin will earn a more-modest patient share of 5 percent, constrained partially by continued uptake of fidaxomicin (Optimer/Cubist's Dificid; Astellas' Dificlir), which has already demonstrated superiority in recurrence rates over oral vancomycin.

"Uptake of surotomycin will likely be constrained, unless it can demonstrate either higher clinical efficacy than Dificid or offer more favorable pricing", said Decision Resources Analyst Maria Ascano Ph.D. "Other factors that will also limit surotomycin's uptake are competition from other emerging therapies like cadazolid (Actelion) and MK-3415A (Merck), generic entry of oral vancomycin capsules, and the continued use of oral preparations of IV vancomycin."

Nevertheless, surveyed hospital pharmacy directors are highly willing to grant favorable formulary inclusion to therapies that provide increased clinical cure rates, particularly in CDI patients that suffer from severe and/or recurrent infections. As a result, market opportunity awaits therapies that can demonstrate higher overall clinical efficacy in patients with difficult-to-treat CDIs.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
3. MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms
4. Eaton Scientific Discusses Positive Anecdotal Feedback from Pharmacist Compounding Homatropine for Doctors Treating Patients Experiencing Hot Flash Symptoms in the Beverley Hills and Los Angeles Area.
5. ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
6. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
7. The Growing Cost of Aging: Express Scripts Study Shows Medication Use for Normal Aging Conditions Overtakes Costs of Treating Most Chronic Diseases
8. The Nairobi Hospital in Kenya Commences Treating Cancer with Advanced Radiotherapy Delivery Using Varian Equipment and Software
9. Varian Medical Systems to Showcase Advanced Technologies for Treating Cancer with Image-Guided Radiotherapy and Radiosurgery at JASTRO Meeting in Tokyo, Japan
10. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
11. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... India , March 24, 2017 Abdominal Aortic Aneurysm Repair ... million by 2022, Globally, registering a CAGR of 5.1% from 2016 to 2022. The ... projected to dominate the market during the study period. ... ... ...
(Date:3/24/2017)... -- Research and Markets has announced the addition ... report to their offering. ... Pain Management in the U.S.: ... physical pain, emphasizing consumer survey analysis, including trends over time. ... who have selected illnesses/conditions strongly associated with physical pain and ...
(Date:3/24/2017)... FinancialBuzz.com News Commentary   ... Medical cannabis products around the world are projected to gain popularity. ... cannabis market will reach a value of USD 55.8 billion by 2025. ... new growing industry. By the end of 2016, 28 states have now ... More conservative states like Arkansas and ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... ... enables researchers to pursue the recent RNA methylation “gold rush” with their established ... of the newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association of Healthcare ... will hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will ... chain and value analysis professionals have a ‘seat at the table’ with clinical ...
(Date:3/27/2017)... ... ... According to the American Cancer Society , the average 15-year survival ... the cancer spreads to other organs, bones, or lymph nodes, however, the 5-year survival ... latter group, tune in to Lifestyle Magazine on April 9, 2017, to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... sodium testing methods are complicated and require expert user knowledge. In a live ... method dedicated to the simplified, yet highly accurate, determination of sodium. , It ...
(Date:3/27/2017)... ... 27, 2017 , ... ?Grow Healthy Vending LLC announced today ... between itself and 1800 Vending DBA Healthy You Vending. (Civil No. 1:14-CV-00121-CW/ United ... announce that we have now reached a settlement agreement regarding the ongoing lawsuits ...
Breaking Medicine News(10 mins):